REFERENCES
- The Swedish National Diabetes Registry. NDR report 2011. (https://www.ndr.nu/; accessed 16 June 2014).
- De Vries JH, Snoek FJ, Kostense PJ, et at. A randomised trial of continuous subcuta-neous insulin infusion system and intensive injection therapy in type 1 diabetes for patients with longstanding poor glycemic control. Diabetes Care 2002;25:2074–2080.
- Bruttomesso D, Crazzolara D, Maran A, et al. In type 1 diabetic patients with good gly-caemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabetic Medicine 2008; 25:326–332.
- Hoogma RP, Hammond PJ, Gomis R, et at. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabetic Medicine 2005;23:141–147.
- Linkeschova R, Raoul M, Bott U, et aL Less severe hypoglycaemia, better metabolic con-trol, and improved quality of life in type 1 diabetes mellitus with continuous subcuta-neous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabetic Medicine 2002;19:746–751.
- Misso ML, Egbets KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus (Review): The Cochrane collaboration 2010; 1:CD005103.
- Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:1–6.
- Garmo A, Garmo H, Arnlöv J, Leksell J. Long-term treatment effects of insulin pump therapy. Practical Diabetes 2011; 28:295–299.
- Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro. Diabetes Care 2001;24:1722–1727.
- Barnard KD, Skinner TC. Qualitative study into quality of life issues surrounding insulin pump use in type 1 diabetes. Practical Diabetes 2007;24:143–148.
- Garmo A, Hornsten A, Leksell J. "The pump was a savior for me". Patients experiences of insulin pump therapy. Diabetic Medicine 2013;30:717–723.
- Ritholtz MD, Smaldone A, Lee J, et aL Perceptions of psychosocial factors and the insulin pump. Diabetes Care 2007; 30:549–554.
- Todres L, Keen S, Kerr D. Continuous sub-cutaneous insulin infusion in type 1 diabetes: patient experiences of "living with a machine". Diabetic Medicine 2010; 27:1201–1204.
- Graneheim UH, Lundman B. Qualitative content analysis in nursing research: con-cepts, procedures and measures to achieve trustworthiness. Nurse Education Today 2004;24:105–112.
- Scheidegger U, Allemann S, Scheidegger K, Diem P. Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Medical Weekly 2007; 137:476–482.
- Bolli G, Kerr D, Reena T, Torlone E, Sola-Gazagnes A, Vitacolonna E, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes. Diabetes Care 2009; 32:1170–1176.